The FDA submission is based on an interim analysis of a phase three trial, which evaluated the drug for the early treatment of Covid-19 in adults at high risk of hospitalization. The drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo.
The two companies in August started testing the antibody on early-stage Covid-19 patients, hoping to keep symptoms from progressing.
This is a developing story. Please check back for updates.
-Reuters contributed to this report.